C-Reactive Protein Test (CRP) Market - 2026-2033

April 2026 | 55 pages | ID: C0DB307A3A9BEN
DataM Intelligence

Abstracts

C-Reactive Protein Test (CRP) Market reached USD 5.34 billion in 2025 and is expected to reach USD 6.08 billion by 2033, growing with a CAGR of 1.68% during the forecast period 2026-2033.

The C-Reactive Protein Test (CRP) Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A C-Reactive Protein Test (CRP) Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Assay type

• Immunoturbidimetric Assay*
• ELISA
• Clinical
• Nonclinical
• Chemiluminescence Immunoassay
• Others

By Detection Type

• hs-CRP*
• Conventional CRP
• cCRP

By Disease area

• Cardiovascular Diseases*
• Cancer
• Rheumatoid Arthritis
• Inflammatory Bowel Disease
• Endometriosis
• Lupus
• Others

By End-user

• Clinics*
• Hospitals
• Laboratories
• Diagnostic Center
• Others

Regional Analysis for C-Reactive Protein Test (CRP) Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global C-Reactive Protein Test (CRP) Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Market Snippet by Assay type
3.2. Market Snippet by Detection Type
3.3. Market Snippet by Disease area
3.4. Market Snippet by End user
3.5. Market Snippet by Region

4. MARKET DYNAMICS

4.1. Market Impacting Factors
  4.1.1. Drivers
    4.1.1.1. The growing popularity of testing methods is expected to drive the market's growth.
  4.1.2. Restraints:
    4.1.2.1. The market is expected to hamper due to the availability of alternative treatments with higher accuracy.
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Forces Analysis
5.2. Epidemiology Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Reimbursement Analysis
5.7. Unmet Needs

6. BY ASSAY TYPE

6.1. Introduction
  6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay type
  6.1.2. Market Attractiveness Index, By Assay Type Segment
6.2. Immunoturbidimetric Assay*
6.3. Introduction
  6.3.1. Market Size Analysis, US$ Million, 2025-2033 and Y-o-Y Growth Analysis (%), 2026-2033
6.4. ELISA
  6.4.1. Clinical
  6.4.2. Nonclinical
6.5. Chemiluminescence Immunoassay
6.6. Others

7. BY DETECTION TYPE

7.1. Introduction
  7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Detection Type
  7.1.2. Market Attractiveness Index, By Detection Type Segment
7.2. hs-CRP*
  7.2.1. Introduction
  7.2.2. Market Size Analysis, US$ Million, 2025-2033 and Y-o-Y Growth Analysis (%), 2026-2033
7.3. Conventional CRP
7.4. cCRP

8. BY DISEASE AREA

8.1. Introduction
  8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease area
  8.1.2. Market Attractiveness Index, By Disease area Segment
8.2. Cardiovascular Diseases*
  8.2.1. Introduction
  8.2.2. Market Size Analysis, US$ Million, 2025-2033 and Y-o-Y Growth Analysis (%), 2026-2033
8.3. Cancer
8.4. Rheumatoid Arthritis
8.5. Inflammatory Bowel Disease
8.6. Endometriosis
8.7. Lupus
8.8. Others

9. BY END-USER

9.1. Introduction
  9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
  9.1.2. Market Attractiveness Index, By End-user Segment
9.2. Clinics*
  9.2.1. Introduction
  9.2.2. Market Size Analysis, US$ Million, 2025-2033 and Y-o-Y Growth Analysis (%), 2026-2033
9.3. Hospitals
9.4. Laboratories
9.5. Diagnostic Center
9.6. Others

10. BY REGION

10.1. Introduction
  10.1.1. Market Size Analysis, US$ Million, 2025-2033 and Y-o-Y Growth Analysis (%), 2026-2033, By Region
  10.1.2. Market Attractiveness Index, By Region
10.2. North America
  10.2.1. Introduction
  10.2.2. Key Region-Specific Dynamics
  10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay type
  10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Detection Type
  10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease area
  10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    10.2.7.1. U.S.
    10.2.7.2. Canada
    10.2.7.3. Mexico
10.3. Europe
  10.3.1. Introduction
  10.3.2. Key Region-Specific Dynamics
  10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay type
  10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Detection Type
  10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease area
  10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    10.3.7.1. Germany
    10.3.7.2. U.K.
    10.3.7.3. France
    10.3.7.4. Italy
    10.3.7.5. Spain
    10.3.7.6. Rest of Europe
10.4. South America
  10.4.1. Introduction
  10.4.2. Key Region-Specific Dynamics
  10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay type
  10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Detection Type
  10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease area
  10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    10.4.7.1. Brazil
    10.4.7.2. Argentina
    10.4.7.3. Rest of South America
10.5. Asia Pacific
  10.5.1. Introduction
  10.5.2. Key Region-Specific Dynamics
  10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay type
  10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Detection Type
  10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease area
  10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    10.5.7.1. China
    10.5.7.2. India
    10.5.7.3. Japan
    10.5.7.4. Australia
    10.5.7.5. Rest of Asia Pacific
10.6. Middle East and Africa
  10.6.1. Introduction
  10.6.2. Key Region-Specific Dynamics
  10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay type
  10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Detection Type
  10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease area
  10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. COMPETITIVE LANDSCAPE

11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking

12. COMPANY PROFILES

12.1. Abbott Laboratories*
  12.1.1. Company Overview
  12.1.2. Product Portfolio and Description
  12.1.3. Key Highlights
  12.1.4. Financial Overview
12.2. F. Hoffmann-La Roche AG
12.3. Merck KGaA
12.4. Randox Laboratories Ltd.
12.5. BODITECH MED INC.
12.6. Abaxis, Inc.
12.7. Thermo Fisher Scientific, Inc.
12.8. Siemens
12.9. Laboratory Corporation of America Holdings
12.10. Beckman Coulter Inc. (Danaher Corporation)(*LIST NOT EXHAUSTIVE)

13. DATAM INTELLIGENCE

13.1. Appendix
13.2. About Us and Applications
13.3. Contact Us